Two Trial Failures; Still Overvalued

Cerecor (CERC) announced the failure of a phase 2 study of CERC-501, its kappa opioid receptor (KOR) antagonist, yesterday morning, sending the stock down by 50% before a meaningful bounce through the afternoon.